Market Overview

TherapeuticsMD to Report Second Quarter 2018 Financial Results on July 30, 2018


-Executive Management to Host Conference Call on July 30, 2018 at 8:30
a.m. ET-

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare
company, today announced that it will report its second quarter 2018
financial results on Monday, July 30, 2018, before the opening of the
U.S. financial markets. Following the announcement, executive management
will host a conference call and webcast at 8:30 a.m. ET on such date to
discuss the Company's financial results and provide a business update.

Conference Call & Audio Webcast Details

Date       Monday, July 30, 2018
Time       8:30 a.m. ET
Telephone Access: U.S. and Canada       866-665-9531
Telephone Access: International       724-987-6977
Access Code For All Callers       8884867

Live Audio Webcast
Home Page or "Investors & Media" Section


A live webcast and audio archive for the event may be accessed on the
home page or from the "Investors & Media" section of the TherapeuticsMD
website at
Please connect to the website prior to the start of the presentation to
ensure adequate time for any software downloads that may be necessary to
listen to the webcast. A replay of the webcast will be archived on the
website for at least 30 days. In addition, a digital recording of the
conference call will be available for replay beginning two hours after
the call's completion and for at least 30 days with the dial-in
855-859-2056 or international 404-537-3406 and Conference ID: 8884867.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women. With its
SYMBODA™ technology, TherapeuticsMD is developing advanced hormone
therapy pharmaceutical products to enable delivery of bio-identical
hormones through a variety of dosage forms and administration routes.
The company recently received FDA approval for TX-004HR, branded as
Imvexxy™ (estradiol vaginal inserts), for the treatment of moderate to
severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to
menopause. The company's late stage clinical pipeline includes TX-001HR
being evaluated for treatment of moderate-to-severe vasomotor symptoms
(VMS) due to menopause. The company also manufactures and distributes
branded and generic prescription prenatal vitamins under the
vitaMedMD® and BocaGreenMD® brands.

Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking
statements. Forward-looking statements may include, but are not limited
to, statements relating to TherapeuticsMD's objectives, plans and
strategies as well as statements, other than historical facts, that
address activities, events or developments that the company intends,
expects, projects, believes or anticipates will or may occur in the
future. These statements are often characterized by terminology such as
"believes," "hopes," "may," "anticipates," "should," "intends," "plans,"
"will," "expects," "estimates," "projects," "positioned," "strategy" and
similar expressions and are based on assumptions and assessments made in
light of management's experience and perception of historical trends,
current conditions, expected future developments and other factors
believed to be appropriate. Forward-looking statements in this press
release are made as of the date of this press release, and the company
undertakes no duty to update or revise any such statements, whether as a
result of new information, future events or otherwise. Forward-looking
statements are not guarantees of future performance and are subject to
risks and uncertainties, many of which are outside of the company's
control. Important factors that could cause actual results, developments
and business decisions to differ materially from forward-looking
statements are described in the sections titled "Risk Factors" in the
company's filings with the Securities and Exchange Commission, including
its most recent Annual Report on Form 10-K and Quarterly Reports on Form
10-Q, as well as reports on Form 8-K, and include the following: whether
the FDA will approve the NDA for the company's TX-001HR product
candidate and whether such approval will occur by the PDUFA target
action date; the company's ability to maintain or increase sales of its
products; the company's ability to develop and commercialize its hormone
therapy drug candidates and obtain additional financing necessary
therefor; whether the company be able to comply with the covenants and
conditions under its term loan agreement; the length, cost and uncertain
results of the company's clinical trials; the potential of adverse side
effects or other safety risks that could preclude the approval of the
company's hormone therapy drug candidates or adversely affect the
commercialization of the company's current or future approved products;
the company's reliance on third parties to conduct its clinical trials,
research and development and manufacturing; the availability of
reimbursement from government authorities and health insurance companies
for the company's products; the impact of product liability lawsuits;
the influence of extensive and costly government regulation; the
volatility of the trading price of the company's common stock and the
concentration of power in its stock ownership. PDF copies of the
company's historical press releases and financial tables can be viewed
and downloaded at its website:

View Comments and Join the Discussion!